The board of directors of Everest Medicines Limited announced that Ms. Lan Kang has been appointed as a non- executive Director of the company with effect from December 22, 2020. Ms. Kang has served at Fosun in multiple roles from 2010 to 2019, including as Executive Board Director and Senior Vice President of Fosun International, responsible for Fosun's insurance business, as well as chief HR of icer at Fosun. She also held the role of non-executive Board Director at a number of healthcare related companies, including Fosun Pharma and Fosun United Health Insurance. Prior to joining Fosun, Ms. Kang spent five years at McKinsey & Company in China, in addition to working as an oncology research scientist in her early career. She is currently a managing director at C-Bridge Value Creation Limited of CBC Group. Ms. Kang was a non-executive director of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. from June 2013 to March 2018 and an executive director of Fosun International Limited from March 2017 to November 2018. Ms. Kang has entered into an appointment letter with the Company for a term of three years commencing from December 22, 2020, subject to (i) retirement from office and re-election at the next general meeting of the Company and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.